Monday 9 November 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX

Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue: +41.2%
EPS: −3.67%
Free cash flow: +79.0%

Quarter to September 2026, against a year earlier

169.00 4.37 +2.65%

Follow NBIX

Alert me

Market cap: $16.7B
P/E: 24.2×
Fwd P/E: 22.5×
Dividend yield: —
F-score: 7/9
ROIC: 17.7%
Net debt / EBITDA: −2.3×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Neurocrine Biosciences, Inc. (NBIX) P/E ratio

Alert me on P/E ratio

As of 9 November 2026, Neurocrine Biosciences, Inc. (NBIX) trades at a P/E ratio of 24.2×. Over the past ten years it has ranged from 0.0× (June 2019) to 1,244× (October 2018); the current reading is higher than 44% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 20.4× and in line with the Healthcare sector median of 25.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/NBIX/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Neurocrine Biosciences, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/NBIX/metrics/pe-ratio">Neurocrine Biosciences, Inc. (NBIX) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	29.4×	(27.14%)
FY2024	40.4×	(22.13%)
FY2023	51.9×	(30.46%)
FY2022	74.6×	(16.81%)
FY2021	89.7×	307.81%
FY2020	22.0×	(91.82%)
FY2019	269×	(17.21%)
FY2018	325×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Sep 2026	20.3×	(14.91%)
Jun 2026	23.9×	21.76%
Mar 2026	19.6×	(33.28%)
Dec 2025	29.4×	(9.66%)
36 more quarters	Free account

Against its own ten years

Low 0.0× High 1,244×

Ten-year median 30.2×

Current reading's percentile 15

Company	P/E ratio
ELAN Elanco Animal Health Incorporated compare	n/m
ALKS Alkermes plc compare	n/m
VTRS Viatris Inc. compare	n/m
ZTS Zoetis Inc. compare	14.0×
UTHR United Therapeutics Corporation compare	20.4×
NBIX Neurocrine Biosciences, Inc.	24.2×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	40.4×
RDY Dr. Reddy's Laboratories Ltd compare	46.0×
KNSA Kiniksa Pharmaceuticals International, plc compare	69.2×
Drug Manufacturers Specialty & Generic industry median	20.4×
Healthcare sector median	25.3×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Neurocrine Biosciences, Inc. (NBIX) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on NBIX

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on NBIX

Stockrow Weekly